What Semax Is
Semax is a synthetic heptapeptide, seven amino acids long, derived from a fragment of adrenocorticotropic hormone, commonly written as ACTH. The exact sequence is the 4 through 7 region of ACTH with a proline-glycine-proline tail attached, which is the modification that gives the molecule its enzyme-resistant character and its long behavioral half-life relative to the parent fragment. The full sequence is Met-Glu-His-Phe-Pro-Gly-Pro.
The peptide was developed in the Soviet Union in the 1980s by researchers at the Institute of Molecular Genetics in Moscow, and it became a registered therapeutic in the Russian Federation for cerebrovascular indications. Outside of Russia, the molecule has not gone through the regulatory pathway that would let it be marketed as a drug, and it sits in the same general educational and research category as most of the peptides discussed in this Academy.
The most important thing to understand about Semax up front is that it does not act on a stress-axis pathway despite being derived from ACTH. The fragment used in Semax is the behaviorally active region of ACTH, not the steroidogenic region, which means the peptide does not stimulate cortisol release. This is a common point of confusion and one that comes up in nearly every educational conversation about the molecule.
Origin: From ACTH Fragment to Russian Stroke Therapy
The Russian research program that produced Semax started from a question about the behavioral effects of ACTH that had been documented in the 1960s and 1970s. Researchers had observed that fragments of ACTH could improve attention, memory consolidation, and recovery from neurological insult in animal models, and the question was whether a synthetic analog could be designed that kept the behavioral activity while removing the steroidogenic activity and improving the stability of the molecule.
The answer that emerged was the ACTH 4-7 fragment with the proline-glycine-proline tail. The tail confers resistance to the peptidases that would otherwise rapidly degrade a fragment of that size, and the 4-7 region carries the behavioral signal without the steroidogenic signal. The result was a molecule that registered as a clinical neurology drug in Russia, primarily for ischemic stroke and for cognitive deficits associated with cerebrovascular disease.
The clinical use pattern in Russia is intranasal administration, and that is the route the Russian literature is built around. The educational community outside Russia has experimented with subcutaneous administration as well, and both routes are discussed below.
The Mechanism: BDNF, NGF, and the Melanocortin System
The mechanism story for Semax has converged on three overlapping pathways in the Russian and international literature. The first is upregulation of brain-derived neurotrophic factor, BDNF, which is the most consistent finding across the published mechanism studies. BDNF is the central signaling molecule for synaptic plasticity and for the survival of neurons under stress, and the upregulation appears to be both rapid and sustained in animal models.
The second pathway is upregulation of nerve growth factor, NGF, which sits alongside BDNF in the neurotrophin family but acts on a different receptor population. The combined upregulation of BDNF and NGF gives the mechanism story its neurotrophic character, which is what underwrites the cognitive and neuroprotective claims in the literature.
The third pathway is the melanocortin receptor system. Because Semax is derived from ACTH, it retains some affinity for melanocortin receptors, particularly MC4R, and this is one of the proposed mechanisms behind the attention and arousal effects that operators report. The melanocortin signal is part of why the peptide is often described as having a stimulant-like quality without being a classical stimulant.
There is also work on dopamine and serotonin system interactions, on cerebral blood flow, and on inflammatory cytokine modulation in injury models, all of which fold into the broader picture of a neurotrophic and neuroprotective compound. The full mechanism story is broader than any single pathway.
The Research Landscape
The published literature on Semax is heavily weighted toward Russian-language journals, which is part of why the molecule is less familiar in Western practice than its research depth would suggest. The Russian work covers acute ischemic stroke, transient ischemic attacks, cognitive deficits in cerebrovascular disease, optic nerve disorders, and a range of pediatric neurology indications. The English-language literature includes a smaller set of mechanism papers, animal studies on memory and attention, and a handful of translation papers that summarize the Russian clinical record.
What is established in the literature: consistent BDNF and NGF upregulation in animal models, neuroprotective effects in ischemia and reperfusion models, and a clinical signal in the Russian stroke literature for accelerated recovery in the acute phase. The mechanism studies have given the field a workable picture of how the molecule acts on the neurotrophin system.
What is not established in the Western sense: high-quality randomized human trials of the kind that would support a regulatory filing outside Russia. The Russian clinical record is real, but it is not the same as the multi-center, double-blind, placebo-controlled trial structure that would let a Western clinician give a confident effect size for a cognitive enhancement claim. This is the most important thing to be honest about, and the educational interest in the compound rests on the mechanism story, the Russian clinical record, and the consistent animal data, not on the kind of trial data that would let anyone make medical claims.
Educational Dosing Reference
The dosing range that shows up most consistently in the educational literature for cognitive use is 300 to 600 micrograms per day, administered intranasally in divided doses, with a typical pattern of one dose in the morning and a second dose in the early afternoon. This is not medical advice. It is a description of where the published Russian protocols and the operator community have converged.
Intranasal administration is the route the Russian clinical literature is built around, and it is the route that produces the clearest signal in the published work. The peptide crosses the nasal mucosa into the systemic circulation and, by some accounts, also reaches the central nervous system through the olfactory pathway, though the relative contribution of the two routes is still debated.
Subcutaneous administration is an alternative that some operators use, with dosing typically in the same 300 to 600 mcg range, once daily or split into morning and afternoon doses. The subcutaneous route is less well documented in the formal literature than the intranasal route, and the educational consensus is that intranasal remains the route with the most supporting work.
Intranasal vs Subcutaneous Route Considerations
The intranasal route is what the Russian clinical record is built around, and it is the route that operators report the most reliable signal from. The peptide is typically reconstituted into a saline-based nasal spray or, in some operator setups, drawn into a fine-tipped syringe and dripped into each nostril with the head tilted back. The dose is split between the two nostrils and the operator stays with the head tilted for about 30 seconds to keep the liquid in contact with the mucosa.
The subcutaneous route is the alternative for operators who do not have access to a usable intranasal preparation or who prefer the dosing precision that an insulin syringe gives. The signal subcutaneously is reported to be present but less crisp than the intranasal signal, which is consistent with the absorption-pathway differences between the two routes.
For client-facing protocols, the educational consensus is that intranasal use sits in a research and personal-experimentation category rather than in a structured client deliverable. The route is real and it is what the literature is built on, but the formal protocols THE PIVOTAL PROTOCOL Academy teaches are anchored in subcutaneous routes for documentation reasons.
Storage and Stability
Lyophilized Semax is stable at room temperature for the medium term, but the educational best practice is to store the unreconstituted vial in a refrigerator and to keep it out of direct light. Once reconstituted with bacteriostatic water or with the saline preparation used for the intranasal spray, the vial moves to the refrigerator immediately and stays there.
The reconstituted shelf life that shows up most often in the educational literature is 30 days at refrigerator temperature, which is also the stability window that bacteriostatic preservatives are rated for. For intranasal spray preparations made with plain saline rather than bacteriostatic water, the shelf life is shorter, and the educational recommendation is to make smaller batches more frequently rather than to extend a single batch past 14 days.
Light exposure is more of a concern for Semax than for some of the other peptides in this category, and the educational practice is to keep the vial in its original packaging or in a small opaque container while it is in the refrigerator.
Semax vs Selank
Selank is the most common comparison point for Semax because the two peptides came out of the same Russian research program and they are often discussed as a pair. The two molecules are not the same and they do not produce the same effects.
Semax sits on the cognitive-enhancement and neuroprotective side. The mechanism story centers on BDNF, NGF, and the melanocortin receptor system, and the operator-reported signal is on attention, memory consolidation, and a stimulant-like quality of mental energy without the side effects of a classical stimulant.
Selank sits on the anxiolytic and stress-modulation side. It is derived from a fragment of tuftsin rather than from ACTH, and the mechanism story centers on GABAergic and serotonergic modulation rather than on the neurotrophin system. The operator-reported signal is on calm focus, reduced anxiety, and improved sleep architecture rather than on cognitive activation.
The two peptides are sometimes used together in the educational literature, with Semax in the morning for cognitive activation and Selank in the evening for anxiolytic and sleep support. This is a common pairing in the Russian-derived nootropic protocols that the international community has experimented with.
Common Reasons People Do Not See Results
The most common reason operators report a flat result with Semax is dose math error. The intranasal route in particular is sensitive to volume calculations, and a dropper or spray that is delivering half the intended dose per actuation is a common failure mode. The first place to look when the signal is weak is the dose calculation, the volume per drop or per spray, and the actual delivered amount.
The second most common reason is the wrong dosing window. Semax has a relatively short window of acute action, and operators who dose only once in the morning and expect a sustained effect through the afternoon may be missing the second dose that the Russian protocols typically include.
The third reason is route mismatch. Operators who use the subcutaneous route and expect the same crispness as the intranasal route, or operators who use a nasal spray with a poor delivery profile and expect the dosing precision of an insulin syringe, are working in a route-effect gap that the literature has documented.
The fourth reason is cycle length. The Russian protocols are typically 14 to 28 days of consistent use, and operators who stop at 5 to 7 days because they have not seen a dramatic change may simply have stopped before the protocol had a chance to produce its effect.
Cycling Considerations
The educational pattern for Semax is shorter cycles than for many of the other peptides in this category. A typical protocol is 14 to 28 days of daily use followed by an evaluation period of 1 to 2 weeks off. The rationale for the off-period is twofold: it gives the operator a clean baseline to compare against, and it avoids the receptor-level adaptation that could blunt the signal over a long continuous run.
For acute cognitive demand contexts, a shorter and more intensive 14-day protocol is common. For longer-running cognitive support, the 28-day pattern with a 14-day off-period is more typical, with re-evaluation at the end of each cycle.
Stacking with other compounds, particularly Selank as discussed above, is common in the educational literature, and the cycling pattern for the stack typically follows the more conservative of the two compound cycles rather than running each on its own independent schedule.
The Educational Framework
Everything above is educational. None of it is medical advice. THE PIVOTAL PROTOCOL Academy exists to teach operators how to think about these compounds at the same level of rigor a research scientist would think about them, which means understanding the literature, understanding the mechanisms, understanding the dosing math, and understanding where the data ends and the speculation begins.
If you are working through Semax for the first time, the right next step is the free Academy course, which covers reconstitution, dosing math, lab work, and the cycling framework in detail. You can join below.
Join the free Academy
Get the full peptide education library, reconstitution worksheets, lab tracking templates, and the cycling framework.